Those authors showed that MSCs treatment induced a more regulatory phenotype with the production of IL-4 and IL-10, but also of IFN-γ, and a systemic decrease of pathogenic antibodies, thus demonstrating the potential value of MSCs treatment in resistant arthritis. The gene discussed is IL10; the disease is arthritic joint disease.